Advertisement

Topics

Amgen's Aimovig Aims To Capture As Many Migraine Patients As Possible With $6,900 Price

17:49 EDT 17 May 2018 | SCRIP

Amgen and Novartis won the first US FDA approval for a CGRP inhibitor in the prevention of migraine headaches. The...

      

Related Stories

 

Original Article: Amgen's Aimovig Aims To Capture As Many Migraine Patients As Possible With $6,900 Price

NEXT ARTICLE

More From BioPortfolio on "Amgen's Aimovig Aims To Capture As Many Migraine Patients As Possible With $6,900 Price"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...